Acute toxicity is a dose-limiting factor for intravenous polymyxin B: A safety and pharmacokinetic study in healthy Chinese subjects

Xiaofen Liu,Yuancheng Chen,Haijing Yang,Jian Li,Jicheng Yu,Zhenwei Yu,Guoying Cao,Xiaojie Wu,Yu Wang,Hailan Wu,Yaxin Fan,Jingjing Wang,Jufang Wu,Yi Jin,Beining Guo,Jiali Hu,Xingchen Bian,Xin Li,Jing Zhang
DOI: https://doi.org/10.1016/j.jinf.2021.01.006
IF: 28.2
2021-02-01
Journal of Infection
Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Objectives</h3><p>Polymyxin B is a last-line antibiotic for multidrug-resistant gram-negative bacterial infections. However, limited safety and pharmacokinetic information is available. We investigated the safety and pharmacokinetics of intravenous polymyxin B in healthy subjects.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Methods</h3><p>An open-label, single-dose clinical trial was conducted in healthy Chinese subjects. Polymyxin B (sulphate) was administered intravenously at 0.75 or 1.5 mg/kg (<em>n</em>=10 per dose, 5 males and 5 females) to examine the safety and pharmacokinetics.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Results</h3><p>One female subject in the 1.5-mg/kg group discontinued due to abdominal pain during administration. The most frequently reported adverse events were perioral paraesthesia, dizziness, and numbness of extremities (7/10 subjects in the 0.75-mg/kg group, all subjects in the 1.5-mg/kg group). All neurotoxicity-related events dissipated without treatment within a maximum of 23 h. Notably, abdominal pain (3/5) and vulvar pruritus (2/5), colpitis (2/5) or abnormal uterine bleeding (1/5) were reported in female subjects receiving the 1.5-mg/kg dose. In the 0.75-mg/kg group, the total clearance, volume of distribution and half-life of polymyxin B were 0.028±0.002 L/h/kg, 0.219±0.023 L/kg and 5.44±0.741 h, respectively; similar values were observed in the 1.5-mg/kg group. Urinary recovery was 3.7±1.1% and 8.1±1.3% in the 0.75- and 1.5-mg/kg groups, respectively. Population pharmacokinetics of polymyxin B was consistent with a three-compartment model. The clearance and distribution of the central compartment were 0.027 L/h/kg and 0.071 L/kg, respectively.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">Conclusions</h3><p>This study is the first to examine the safety and pharmacokinetics of polymyxin B in healthy subjects. Our results highlight that acute toxicity is a dose-limiting factor for intravenous polymyxin B.</p>
infectious diseases
What problem does this paper attempt to address?